Replies to post #96824 on Biotech Values

[Californicator]

Hey Dew..........Nice board. Thanks for the heads up. Looks like a lot of good info here. Mark for the board.

[wallstarb]

ASCO pretty much a bust this year for small cap biotechs. Some interesting studiez anddata from some of the big pharma/biopharma, but nothing really earth shattering for smaller cap stocks which would really have significant %moves based on data.

Going forward with ASCO out of the way there will be a HUGE slowdown in newsflow for biotech in general and with that I would expect interest to wane as mauch of the "fast money" sells or has sold and the demand from those sorts of investors/traders leave the sector post ASCO.

I am keeping our short bias for the next few months but will be on the looout for any screaming bargains not many I see right now, but I am noticing some starting to seem more interesting.

Hopefully a number of these stocks can take advantage of their high prices to raise some cash.

[DFRAI]

Not all was lost at ASCO- ONCY

one of the collaborators with ONCY got a 450k grant for his work with viruses in collorectal cancer and he won it over 32 other drugs i believe. the only virus work he has done was with reovirus. Last year we saw that ASCO acknowledged the KRAS pathway - this just plays into ONCY strenght.

I believe "a novel therapeutic approach for patients with KRAS mutant metastatic colorectal cancer" refers to Dr. Goel's involvement in the new REO 022 Kras colon cancer. Congrats to Dr. Goel for being awarded this $450k grant for 3 yrs. It's a very decent amount of funding. On top of that, as a young investigator, this will certainly be a big boost to his career particularly if he holds a tenure track position. I suspect a promotion is coming soon.

"ALEXANDRIA, Va. – Improving the lives of breast cancer survivors, a novel therapeutic approach for patients with KRAS mutant metastatic colorectal cancer, and the development of a new molecular imaging device that could potentially be used to identify patients with microscopic residual cancer are among the research studies being conducted by gifted grant and award recipients."

Dr. Goel is one of three recipients in his category:

Advanced Clinical Research Awards (ACRA) are presented to physicians who have 5 to 10 years of experience and are full-time faculty members in a clinical setting at an academic medical center. Each winner will receive a 3-year award totaling $450,000 to support original research currently not funded. This year's recipients were chosen for their unique, patient-oriented approaches to research in sarcoma, breast cancer and colorectal cancer. The 2010 recipients are:

David G. Kirsch, MD, PhD
Duke University Medical Center

Isabelle Bedrosian, MD
The University of Texas M. D. Anderson Cancer Center

Sanjay Goel, MD, MS
Montefiore Medical Center